Mortality reduction by vitamin D receptor activation in end-stage renal disease: A commentary on the robustness of current data

Nephrology Dialysis Transplantation

Volumn 24, Issue 3, 2009, Pages 703-706

  Vervloet, Marc G ^a   Twisk, Jos W R ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical trials; Methodology; Mortality; Vitamin D receptor activation

Indexed keywords

VITAMIN D RECEPTOR;

ARTICLE; CONTROLLED STUDY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT RESPONSE;

HUMANS; KIDNEY FAILURE, CHRONIC; RECEPTORS, CALCITRIOL; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 60749130276     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn492     Document Type: Article

References (25)

1. Teng M, Wolf M, Ofsthun MN et al. Activated injectable VDRA and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
2. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
3. Shoji T, Shinohara K, Emoto M et al. Lower risk for cardiovascular mortality in oral 1?-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184
4. Tentori F, Hunt WC, Stidley CA et al. Medical directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving VDRA analogs. Kidney Int 2006; 70: 1858-1865
5. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
6. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840-853
7. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Int Med 2007; 167: 1730-1737
8. Andress DL. VDRA in chronic kidney disease: a systemic role for selective VDRA activation. Kidney Int 2006; 69: 33-43
9. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl Med 2003; 349: 446-456
10. Rashid G, Bernheim J, Green J et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007; 292: F1215-F1218
11. Kestenbaum B, Andress DL, Schartz SM et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: 2010-2016
12. Block GA, Klassen PS, Lazarus M et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
13. Qiao G, Kong J, Uskokovic M et al. Analogs of 1alpha, 25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96: 59-66
14. Li YC, Kong J, Wei M et al. 1,25 dihydroxyvitamin D(3) is a negative endocrine regulator of the rennin-angiotensin system. J Clin Invest 2002; 110: 229-238
15. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
16. Bodyak N, Ayus JC, Achinger S et al. Activated vitamin D attenuates left ventricular abnormalities by dietary sodium in Dahl salt-sensitive animals. PNAS 2007; 104: 16810-16815
17. Kim WH, Park CW, Shin YS et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2006; 102: c21-c29
18. Mak RHK. 1,25 Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53: 1353-1357
19. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patient with kidney disease? Kidney Int 2005; 68: 1973-1981
20. Mathieu C, Adorini L. The coming of age of 1,25 dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 2002; 8: 174-179
21. Liu PT, Strenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773
22. Gorham ED, Garland CF, Garland FC et al. Optimal vitamin D status for colorectal cancer prevention. Am J Prev Med 2007; 32: 210-216
23. Vieth R. Vitamin D toxicity, policy and science. J Bone Miner Res 2007; 22(Suppl 2): V64-V68
24. Coen C, Manni M, Agnoli A et al. Cardiac calcifications; fetuin-A and other risk factors in haemodialysis patients. ASAIO J 2006; 52: 150-156
25. Bolland MJ, Barber PA, Doughty RN et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008; 336: 262-266